CN114129474B - 一种无菌贴膜及其制备方法 - Google Patents
一种无菌贴膜及其制备方法 Download PDFInfo
- Publication number
- CN114129474B CN114129474B CN202111189968.XA CN202111189968A CN114129474B CN 114129474 B CN114129474 B CN 114129474B CN 202111189968 A CN202111189968 A CN 202111189968A CN 114129474 B CN114129474 B CN 114129474B
- Authority
- CN
- China
- Prior art keywords
- mixed solution
- trehalose
- parts
- electron beam
- essence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 230000001954 sterilising effect Effects 0.000 claims abstract description 37
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 30
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 30
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 29
- 239000011259 mixed solution Substances 0.000 claims abstract description 23
- 238000010894 electron beam technology Methods 0.000 claims abstract description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 19
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical class C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 16
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 14
- 239000000230 xanthan gum Substances 0.000 claims abstract description 14
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 14
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 14
- 229940110456 cocoa butter Drugs 0.000 claims abstract description 13
- 235000019868 cocoa butter Nutrition 0.000 claims abstract description 13
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 8
- 230000001815 facial effect Effects 0.000 claims abstract description 8
- 239000007908 nanoemulsion Substances 0.000 claims abstract description 8
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000008367 deionised water Substances 0.000 claims abstract description 7
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 34
- 238000003756 stirring Methods 0.000 claims description 9
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 230000005540 biological transmission Effects 0.000 claims description 5
- 238000005516 engineering process Methods 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 239000003094 microcapsule Substances 0.000 claims description 4
- 239000000498 cooling water Substances 0.000 claims description 3
- 238000007599 discharging Methods 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 238000001228 spectrum Methods 0.000 claims description 2
- 230000008591 skin barrier function Effects 0.000 abstract description 7
- 239000007788 liquid Substances 0.000 abstract description 6
- 230000035699 permeability Effects 0.000 abstract description 5
- 230000000638 stimulation Effects 0.000 abstract description 4
- 210000003491 skin Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 8
- 201000004624 Dermatitis Diseases 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 230000003020 moisturizing effect Effects 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 208000003251 Pruritus Diseases 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 206010040882 skin lesion Diseases 0.000 description 4
- 231100000444 skin lesion Toxicity 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- 206010040844 Skin exfoliation Diseases 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000035618 desquamation Effects 0.000 description 3
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 235000009470 Theobroma cacao Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 1
- -1 DPPH free radical Chemical class 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010053177 Epidermolysis Diseases 0.000 description 1
- 206010051814 Eschar Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000589634 Xanthomonas Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 231100000333 eschar Toxicity 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 150000002840 non-reducing disaccharides Chemical class 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 229940067631 phospholipid Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0212—Face masks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/81—Preparation or application process involves irradiation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明提供一种无菌贴膜的制备方法,包括:将海藻糖、氢化磷脂和、胆固醇混合均匀,通过高压均质机进行压力处理,得到外观呈半透明的海藻糖纳米乳液;将去离子水、1,2‑戊二醇和所述海藻糖纳米乳液预混,得到第一混合溶液,待所述第一混合前述溶液充分溶解后,将预混的甘油、黄原胶加入配液罐所述第一混合溶液中,得到第二混合溶液;将可可脂加入到配液罐所述第二混合溶液中,得精华液;将面膜纸放置到面膜袋中,加入所述精华液,得到所述无菌贴膜敷贴产品;其中采用电子束消毒灭菌装置对面膜进行灭菌。本方法具有安全性高,无刺激,渗透性好,可修复受损的皮肤屏障的特点。
Description
技术领域
本发明涉及医疗技术领域,尤其涉及一种无菌贴膜并能辅助治疗与皮肤屏障受损相关皮肤病的功效性护肤品及其制备方法。
背景技术
目前,面膜产品是生活中的必需品,然而,由于面膜中水的含量非常高,容易受微生物污染,所以面膜的灭菌和防腐处理工艺有较高的要求。现有的面膜通常添加防腐剂,防腐剂可以保护面膜产品免受微生物污染、变质,以延长产品的货架寿命。现有的面膜通常添加除菌剂以达到抗菌/灭菌的效果。但这些添加剂对于皮肤本身而言是无用成分,甚至可能会增加肌肤的刺激性和致过敏性等。为确保产品的安全性,防止消费者因使用受微生物污染的产品而引起可能的感染,防腐剂和除菌剂的剂量需要达到一定要求,如果防腐剂/除菌剂添加的量不够,则可能出现微生物适应周围的生长环境,产生抗药性,从而导致防腐失效。一般来说,为了达到防腐和抗菌的功能,市面上大多数都是复配防腐剂/除菌剂。
疫情或秋冬季节长时间戴口罩,皮肤长期与口罩摩擦也会造成皮肤瘙痒、红肿等情况发生,部分人会引起接触性皮炎。另外,随着科技的进步,水光、果酸换肤等医学美容被越来越多的人诉求。而这些肌肤由于皮肤屏障受损,非常敏感脆弱。因此开发中一种不含抗菌剂,安全、无刺激,适用于皮肤屏障受损、易被吸收的无菌面膜具有极其重要的意义。
发明内容
有鉴于此,本发明提供一种无菌贴膜及其制备方法,至少部分解决现有技术中存在的问题。具有安全性高,无刺激,渗透性好,可修复受损的皮肤屏障的特点。
本申请提供一种无菌贴膜的制备方法,具体包括如下步骤:
步骤1:将海藻糖、氢化磷脂和胆固醇混合均匀,通过高压均质机进行压力处理,所述高压均质机压力设置为400bar-1200bar,所述压力处理重复执行直到得到外观呈半透明的海藻糖纳米乳液;步骤2:将去离子水、1,2-戊二醇和所述海藻糖纳米乳液预混,得到第一混合溶液,搅拌所述第一混合溶液并同时对所述第一混合溶液进行低温加热;步骤3:待所述第一混合溶液充分溶解后,将预混的甘油和黄原胶加入所述第一混合溶液中,持续搅拌并保温,直至混合均匀,开启冷却水降温,得到第二混合溶液;步骤4:将可可脂加入到所述第二混合溶液中,静置到可可脂和所述第二混合溶液混合均匀后搅拌,降温至40℃,出料得精华液;步骤5:将面膜纸放置到面膜袋中,加入所述精华液,封口,进行电子束消毒灭菌,得到所述无菌贴膜产品;其中所述电子束灭菌采用电子束消毒灭菌装置进行,将所述面膜袋放入托盘中,使所述面膜袋均匀覆盖托盘底部,将所述托盘放入传输链上,待所述传输链运转一圈后,将所述面膜袋翻转,所述传输链继续运转一圈,辐照剂量设定为14-22KGy。
本申请还提供通过上述方法制备的无菌贴膜,其特征在于,所述无菌贴膜包括面膜布和精华液,所述精华液包括海藻糖、氢化磷脂、胆固醇、黄原胶、可可脂、甘油、1,2-戊二醇和去离子水。
进一步地,精华液包括:海藻糖0.1-5份、氢化磷脂0.1-3份、胆固醇0.1-4份、黄原胶0.1-0.5份、甘油3-8份、1,2-戊二醇1-6份、可可脂0.5-8.0份和去离子水加至100份。
本申请用氢化磷脂通过包裹技术将海藻糖包裹在纳米级的微囊中,制备成海藻糖纳米透明乳液,大大提高了海藻糖的透皮吸收和生物利用率,使得其真正能够发挥功效。本申请通过14-22KGy的辐照剂量进行电子束灭菌方法进行灭菌,具有安全性高,无刺激,渗透性好,可修复受损的皮肤屏障的特点。其次,电子束灭菌既能穿透产品包装袋从而确保产品无菌,同时还能保护内部的产品和介质不受电子束穿透以及X射线和类似辐射的损伤,并且能避免产品包装变形。
附图说明
为了更清楚地说明本发明实施例的技术方案,下面将对实施例中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其它的附图。
图1为不同实施例的效果比较示意图,从上到下从左到右依次对应实施例1-5。
图2为无菌贴膜的包装展示图。
图3为不同实施例DPPH清除率的示意图。
具体实施方式
下面结合附图对本发明实施例进行详细描述。
可可脂是可可豆中的天然植物硬脂,具有润滑的质感和浓郁醇厚的天然可可香气,塑性范围小,熔点接近人体皮肤温度,极易被熔解吸收,是很好的水合保湿剂和润滑剂。可可脂含有丰富的多酚物质,具有减少和消除自由基、抗氧化和抗脂质过氧化性能,其活性比茶和红酒高。天然可可脂中脂肪酸成分主要为硬脂酸、油酸和棕榈酸,其中硬脂酸含量很高,可以降低血液中的胆固醇。
黄原胶是一种亲水胶,可在液体和半固体制剂的多相体系中作为有效的增稠剂、乳化剂、助悬剂和稳定剂。黄原胶的高黏性使外用制剂更易于涂布,且水分挥发后药物不易从皮肤上脱落,提高了药物的生物利用度和用药舒适感。在固体制剂中,黄原胶作为黏合剂时其制片黏合力强,且片剂不会过于坚硬;具有良好的膨胀、润湿和毛细管作用,又是良好的崩解剂,既适用于水溶性药物,也适用于水难溶性药物;黄原胶是国际上微胶囊药物囊材中的功能组分,在控制药物释放方面起重要作用。此外,研究表明黄原胶寡糖具有清除羟基自由基能力,并能激活植物防卫系统以抵御病原菌的侵染,同时对甘蓝黑腐病黄单孢菌也具有抑菌活性;黄原胶应用化学改性中接枝共聚方法生产的衍生物,在抗生素药物固载和控释方面占有重要地位随着现代生化技术的发展,黄原胶在医药领域越来越显示着其重要性。
海藻糖是一种天然二糖,在自然界动植物和微生物中广泛存在,经过多年研究,现已进入较大规模的工业化生产阶段。由于海藻糖的结构不同于其他低聚糖,是一种由两个吡喃环葡萄糖分子组成的非还原性双糖,通过α,α-1,1糖苷键连接,自身性质非常稳定,化学名为α-D-吡喃葡糖基α-D-吡喃葡糖苷(α-D-glucosideo-α-glucosideo),分子式C12H22O11·2H2O,分子量为378.33,结构对称。这种α,α-1,1糖苷键键能较低,不易被分解,由于结构的特异性,也就赋予了它独特的理化性质和生物学功能。海藻糖能够在细胞表层形成一层保护膜,减少皮肤表面水分蒸发,令水分自由扩散到角质层,从而有效地保湿润肤和保护细胞膜的功能。提高细胞的耐高温、抗干燥、抗冷冻能力,从而提高皮肤适应环境能力。同时海藻糖是一种潜在的自由基清除剂,具有抗氧化的作用。海藻糖还可与其他多糖在胞外基质中形成一层保护膜,降低皮肤表面水分的蒸发,从而实现保湿润肤的功效。强紫外线时,在细胞表面形成特殊的保护膜,避免晒伤,减少黑色素沉淀,有效预防衰老。
电子束消毒灭菌装置,是本申请采用的灭菌装置,通过包括外壳,用于放置被灭菌产品的托盘,传输托盘的传送装置如传输链等,以及用于辐照灭菌的辐照装置。本申请通过多次实验,获得最佳灭菌的辐照设置,即,电子束消毒灭菌装置采用10Mev行波电子直线加速器,能产生具有多或单能谱性质电压高于100KV但低于300KV直接赋能的电子束,辐照剂量采用14-22KGy。与传统的高压蒸汽灭菌、化学灭菌法相比,具有灭菌彻底、操作安全、无残留、不污染环境等优点。与传统的γ射线辐照(如钴60辐照)方法相比,电子束辐照具有有高剂量率、辐照时间短、高灵活性、高精准性、低损害性等优势,能在几秒钟内即完成高剂量的辐照过程,对活性成分影响极低。14-22KGy的辐照剂量是通过多次实验确定,此剂量既可以高效彻底灭菌,又保证产品性能不受辐照损伤,活性成分受辐照影响最小,达到了最优的效果。
针对现有的面膜渗透性较差,本发明用氢化磷脂通过包裹技术将海藻糖包裹在纳米级的微囊中,制备成海藻糖纳米透明乳液,大大提高了海藻糖的透皮吸收和生物利用率,使得其真正能够发挥功效。在保证本申请面膜功效的基础上,采用14-22KGy的辐照剂量进行电子束灭菌,有效对产品进行灭菌,保证产品无菌的同时保护内部的产品和介质不受电子束穿透以及X射线和类似辐射的损伤,并且能避免产品包装变形。具有安全性高,无刺激,渗透性好,可修复受损皮肤屏障等特点。
以下实施例进一步描述和证实本发明范围内的优选实施方式。这些实施仅仅是为了证明本发明,只要各种变化是可能的且不背离本发明的主旨和范围,则并不对本发明构成限制。
表1实施例1-5的配方(单位为重量份)
按照各实施例取各个原料;将海藻糖、氢化磷脂、胆固醇在60-90℃混合均匀,通过高压均质机处理,高压均质机压力400bar-1000bar,循环2-5次,得到外观呈半透明的海藻糖纳米乳液;
将去离子水、1,2-戊二醇和海藻糖纳米乳液预混,加入到配液罐中,搅拌,加热至80℃,保温;
待前述溶液充分溶解后,将预混的甘油、黄原胶加入配液罐中,持续搅拌,保温约20min,开启冷却水,降温至50℃左右;
将可可脂加入到配液罐中,均质5min,搅拌约30min,继续降温至37℃左右,出料得精华液。
将面膜纸放置到面膜袋中,加入精华液,封口,电子束灭菌或者湿热灭菌,得到所述无菌敷贴产品。
将各实施例的产品分别进行电子束灭菌和湿热灭菌,电子束灭菌剂量为22kGy,湿热灭菌参数为121℃,12min。灭菌结束后,进行检测,结果如表2所示。
表2两种灭菌方式比较
由表2可以看出,虽然湿热灭菌也能保证产品无菌,但存在安全隐患,且产品包装易变形、易漏液。电子束辐照灭菌是有效的低温灭菌方式,不发生热的交换、压力差别和扩散层干扰,辐照射线穿透力强,产品包装完成后一起进行灭菌,操作简单,可以连续操作,可实现大规模商业化生产。
分别检测实施例和对比例的初始污染菌数量和辐照剂量。初始污染菌检测方法:依据GB/T19973.1-2015医疗器械的灭菌-微生物方法-第1部分:产品上微生物总数的测定。辐照剂量选定参考依据:GB18280.2-2015医疗保健产品灭菌辐射第2部分,结果如表3所示。
表3实施例1-5的辐照剂量
由表3可以看出,添加适量的1,2-戊二醇,有效降低产品灭菌前初始污染菌数量,从而使得较低辐照剂量即可杀灭产品中的微生物,降低产品辐照过程中部分原料降解,保证产品无菌。在辐照保证无菌剂量14KGy时,产品无杂质,稀稠度与辐照前状态差异不大,可见在此辐照剂量下,保证了灭菌效果的同时也保证了产品的有效性。在14.2KGy、15.2KGy和17.6KGy时,产品状态和14KGy时相似,可见在这些辐照剂量下,也可以达到和14KGy同样的效果。在辐照保证无菌剂量22KGy时,产品变稀,味道刺鼻,虽然也可以达到预期的灭菌效果,但是对产品效果有一定的损伤。
一、皮肤刺激试验
采用健康新西兰白色纯种大白兔21只,体重不低于2kg,实验前4h将动物背部脊柱两侧被毛除去,范围约为10cm*10cm,作为试验和观察部位,分为7组,将实验品涂抹在左侧,右侧作为空白对照,将左侧涂抹实验品后用绷带固定4好,结束后拆除绷带,用蒸馏水洗去残留实验品。观察拆除绷带后1h、24h、48h和72h涂抹实验品部位及周围皮肤组织反应,包括红斑、焦痂、水肿和坏死等并做好记录。
表4皮肤刺激性实验结果
二、临床疗效
2020年09月-2020年12月,对本发明进行了内控临床疗效观察。本组患者共62例,均为门诊病人。其中女39例,男23例,年龄18-37岁,平均26.2岁,病程3个月-6年,平均2.8年;原发疾病有化妆品皮炎、敏感性皮炎、激素依赖性皮炎、皮炎湿疹、痤疮性皮炎等。
1、临床表现和症状:灼热瘙痒、疼痛、脱屑或紧绷感、红斑、毛细血管扩张或潮红水肿、丘疹或脓疱、色素沉着或表皮萎缩。
2、治疗方法:用本发明制备的贴敷,每周2-3次,连用4周。
3、疗效标准:4周后,对面部潮红、干燥脱屑、色素、痤疮样皮疹和瘙痒不适感进行评价。
a痊愈:皮肤损害完全消退,自觉症状完全消失。
b显效:皮肤损害消退>70%,自觉症状完全消失。
c有效:皮肤损害30%-70%自觉症状减轻。
d无效:皮肤损害消退<30%,自觉症状未改善。
(痊愈率加显效率,合计为有效率)
4、结果统计
痊愈42例,显效11例,有效7例,无效2例,有效率85.5%。潮红改善的有效率为96.8%;干燥脱屑改善的有效率为93.5%;色素改善的有效率为77.4%;痤疮样皮疹改善的有效率为80.6%;瘙痒及不适症状改善的有效率为95.2%。
三、保湿效果
采用德国COURAGE+KHAZAKA(CK)公司生产的皮肤水分测量仪测量志愿者的皮肤改善情况。
表5志愿者5周前后的平均含水量(%)变化
实施例1 | 实施例2 | 实施例3 | 实施例4 | 对比例 | |
5周前 | 44.35 | 45.62 | 45.24 | 44.39 | 44.64 |
周后 | 72.16 | 71.38 | 70.81 | 70.35 | 45.37 |
由上表的数据明显得出试验组的保湿效果要高于对照组的保湿效果,说明本发明对皮肤的保湿效果显著。
四、DPPH自由基清除率的测定
取2.0mL DPPH溶液(溶剂为无水乙醇),加入各实施例,混合后25℃避光反应1h,在517nm下测量吸光度为AS;对照组为2.0mL乙醇溶液和2.0ml样品,吸光度为Ab;空白组为2.0mLl乙醇溶液和2.0mL DPPH溶液,吸光度为A0。
DPPH自由基清除率计算公式:
DPPH清除率=(1-(AS-Ab)/A0)×100
结合图3,可见本产品具有较好的DPPH自由基清除率,8%可可脂具有81.53%的DPPH自由基清除率。
需说明的是,在不冲突的情况下,以下实施例及实施例中的特征可以相互组合;并且,基于本公开中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本公开保护的范围。
需要说明的是,下文描述在所附权利要求书的范围内的实施例的各种方面。应显而易见,本文中所描述的方面可体现于广泛多种形式中,且本文中所描述的任何特定结构及/或功能仅为说明性的。基于本公开,所属领域的技术人员应了解,本文中所描述的一个方面可与任何其它方面独立地实施,且可以各种方式组合这些方面中的两者或两者以上。举例来说,可使用本文中所阐述的任何数目个方面来实施设备及/或实践方法。另外,可使用除了本文中所阐述的方面中的一或多者之外的其它结构及/或功能性实施此设备及/或实践此方法。
以上所述,仅为本发明的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,可轻易想到的变化或替换,都应涵盖在本发明的保护范围之内。因此,本发明的保护范围应以权利要求的保护范围为准。
Claims (2)
1.一种无菌贴膜的制备方法,其特征在于,具体包括如下步骤:
步骤1:将海藻糖、氢化磷脂和胆固醇混合均匀,通过高压均质机进行压力处理,所述高压均质机压力设置为400bar-1200bar,所述压力处理重复执行直到得到外观呈半透明的海藻糖纳米乳液;
步骤2:将去离子水、1,2-戊二醇和所述海藻糖纳米乳液预混,得到第一混合溶液,搅拌所述第一混合溶液并同时对所述第一混合溶液进行低温加热;
步骤3:待所述第一混合溶液充分溶解后,将预混的甘油和黄原胶加入所述第一混合溶液中,持续搅拌并保温,直至混合均匀,开启冷却水降温,得到第二混合溶液;
步骤4:将可可脂加入到所述第二混合溶液中,静置到可可脂和所述第二混合溶液混合均匀后搅拌,降温出料得精华液;
步骤5:将面膜纸放置到面膜袋中,加入所述精华液,封口,进行电子束消毒灭菌,得到所述无菌贴膜产品;
其中所述电子束灭菌采用电子束消毒灭菌装置进行,将所述面膜袋放入托盘中,使所述面膜袋均匀覆盖托盘底部,将所述托盘放入传输链上,待所述传输链运转一圈后,将所述面膜袋翻转,所述传输链继续运转一圈,电子束消毒灭菌装置采用10Mev行波电子直线加速器,能产生具有多或单能谱性质电压高于100kV但低于300kV直接赋能的电子束,辐照剂量设定为14-22KGy,
氢化磷脂通过包裹技术将海藻糖包裹在纳米级的微囊中,制备成海藻糖纳米透明乳液,
所述精华液包括:海藻糖0.1-5份、氢化磷脂0.1-3份、胆固醇0.1-4份、黄原胶0.1-0.5份、甘油3-8份、1,2-戊二醇1-6份、可可脂0.5-8.0份和去离子水加至100份。
2.一种无菌贴膜,其特征在于,所述无菌贴膜通过权利要求1所述的方法制备而成。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111189968.XA CN114129474B (zh) | 2021-10-11 | 2021-10-11 | 一种无菌贴膜及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111189968.XA CN114129474B (zh) | 2021-10-11 | 2021-10-11 | 一种无菌贴膜及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114129474A CN114129474A (zh) | 2022-03-04 |
CN114129474B true CN114129474B (zh) | 2023-06-30 |
Family
ID=80395137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111189968.XA Active CN114129474B (zh) | 2021-10-11 | 2021-10-11 | 一种无菌贴膜及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114129474B (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1679470A (zh) * | 2005-01-12 | 2005-10-12 | 凌沛学 | 用于化妆品的含海藻糖和透明质酸组合物及其制备方法 |
KR20160114777A (ko) * | 2015-03-24 | 2016-10-06 | 주식회사 오브 | 이중 효과 닌자 마스크 |
CN107375032A (zh) * | 2017-08-11 | 2017-11-24 | 天津嘉氏堂科技有限公司 | 一种修复皮肤屏障的组合物及制备方法 |
CN107412255A (zh) * | 2017-08-11 | 2017-12-01 | 天津嘉氏堂科技有限公司 | 皮肤屏障修复组合物及制剂 |
CN107519123A (zh) * | 2017-09-30 | 2017-12-29 | 广州昕生医学材料有限公司 | 面部修复抗炎组合物及其应用 |
KR20200050665A (ko) * | 2018-11-02 | 2020-05-12 | (주)아모레퍼시픽 | 마스크 겔 조성물, 이를 포함한 마스크 팩 시트 및 그 제조방법 |
CN111956860A (zh) * | 2020-09-07 | 2020-11-20 | 海南鸿翼医疗器械有限公司 | 一种皮肤屏障创面修复的液体海藻糖敷料及其制备方法 |
-
2021
- 2021-10-11 CN CN202111189968.XA patent/CN114129474B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1679470A (zh) * | 2005-01-12 | 2005-10-12 | 凌沛学 | 用于化妆品的含海藻糖和透明质酸组合物及其制备方法 |
KR20160114777A (ko) * | 2015-03-24 | 2016-10-06 | 주식회사 오브 | 이중 효과 닌자 마스크 |
CN107375032A (zh) * | 2017-08-11 | 2017-11-24 | 天津嘉氏堂科技有限公司 | 一种修复皮肤屏障的组合物及制备方法 |
CN107412255A (zh) * | 2017-08-11 | 2017-12-01 | 天津嘉氏堂科技有限公司 | 皮肤屏障修复组合物及制剂 |
CN107519123A (zh) * | 2017-09-30 | 2017-12-29 | 广州昕生医学材料有限公司 | 面部修复抗炎组合物及其应用 |
KR20200050665A (ko) * | 2018-11-02 | 2020-05-12 | (주)아모레퍼시픽 | 마스크 겔 조성물, 이를 포함한 마스크 팩 시트 및 그 제조방법 |
CN111956860A (zh) * | 2020-09-07 | 2020-11-20 | 海南鸿翼医疗器械有限公司 | 一种皮肤屏障创面修复的液体海藻糖敷料及其制备方法 |
Non-Patent Citations (3)
Title |
---|
丁利营 ; 李红艳 ; 赵绛波 ; 黄玉成 ; 麻红雨 ; 李楠 ; 毛雨婷 ; .皮肤屏障修复贴海藻糖敷料对面部激光术后皮肤修复的临床观察.中国医疗美容.2017,(01),35-39. * |
张玉华 ; 籍保平 ; 凌沛学 ; 孟一 ; .海藻糖和透明质酸对膜脂双层的保护及其作用机制.食品科学.2007,(08),49-55. * |
徐国防 ; 赵岳 ; 刘平 ; 牛志强 ; .皮脂膜修复贴敷料在皮肤修复中的研究分析.中国医药科学.2016,(03),17-20. * |
Also Published As
Publication number | Publication date |
---|---|
CN114129474A (zh) | 2022-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6645510B1 (en) | Method of treating topical ailments | |
CA2608344C (en) | Method and composition for use in preparation of a patient for surgery | |
US20150264935A1 (en) | Semi-Fluidic Composition for Lubricating, Moisture Retaining, Disinfecting, Sterilizing and Method Using the Same | |
PT789584E (pt) | Aplicacao de superoxido-dismutase (sod) em liposomas | |
US20130059021A1 (en) | Perfluoro(n-butylcyclohexane) compositions and uses thereof | |
JP2021050249A (ja) | ザクロ種子油、rosa canina果実油、およびinula viscosa含油樹脂または抽出物を含有する製剤 | |
JP6293483B2 (ja) | ヒアルロン酸を含む局所用防腐剤無添加組成物 | |
KR20110096054A (ko) | 과불화탄소 겔 배합물 | |
CN109646712B (zh) | 一种胶态硫液体敷料及其制备方法 | |
CN110812298A (zh) | 抑汗杀菌剂、含有该抑汗杀菌剂的祛狐臭剂及其制备方法 | |
KR100673044B1 (ko) | 경피 투여용 국소 조성물 | |
CN104622897A (zh) | 一种治疗皮肤病的护肤液及其制备方法 | |
CN110638727A (zh) | 一种婴幼儿护臀组合物及其制备方法和应用 | |
CN109481391A (zh) | 一种复配银离子与绿酚麴的婴儿护理膏及其制备方法 | |
CN109833431A (zh) | 一种抑菌凝胶及其制备方法 | |
MX2011009935A (es) | Crema medicinal para dermatitis del pañal y un proceso para hacerla. | |
JP2018521992A5 (zh) | ||
CN114129474B (zh) | 一种无菌贴膜及其制备方法 | |
CN111743826A (zh) | 一种祛斑抗皱保湿乳液 | |
RU2475230C1 (ru) | Лечебно-косметическое средство для защиты кожи от солнечных ожогов | |
WO2019123483A1 (en) | A herbal antiseptic and wound healing preparation | |
CN104771750A (zh) | 复方蒙脱石溶菌酶散剂及其制备方法和应用 | |
US20220211606A1 (en) | Liquid composition for influencing the microbiota on a subject's skin comprising chitosan | |
CN107174535A (zh) | 一种具有抗炎透皮修复功效的透明质酸组合物及应用 | |
US8900601B2 (en) | Permeable mixtures, methods and compositions for the skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A sterile film and its preparation method Effective date of registration: 20231007 Granted publication date: 20230630 Pledgee: Xi'an innovation financing Company limited by guarantee Pledgor: XI'AN HUIPU BIOTECHNOLOGY Co.,Ltd. Registration number: Y2023980060192 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |